Narcolepsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Type (Type 1, Type 2, Others), By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others), By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others), By End User (Hospitals, Clinics, Retail Pharmacies, Others), By Region and Competition

Industry : Healthcare
Pages : NA
Published Date : NA

Customization Enquiry

Buy Now

Single User Licence

$4500

Multi-User Licence

$5500

Custom Research Licence

$8000

Summary

Request Sample

Report Description

The global narcolepsy market is anticipated to register an impressive growth rate during the forecast period. This can be ascribed to the rising number and size of investments in the healthcare sector for the treatment of sleep disorders across the region. Additionally, the growing prevalence of neurological disorders such as sleep apnea and insomnia due to stressful lifestyles is expected to drive the growth of the market over the years. Similarly, the major players are investing in the development of narcolepsy drugs at low cost which is expected to further drive the growth of the market over the forecast period. According to Clinical trials. gov,131 studies have been found for narcolepsy drugs. Among them narcolepsy cataplexy-type drugs can be taken by both males and females between 18-55 years age. Moreover, significant improvements in the diagnostic technologies for narcolepsy and pharmaceutical companies are developing variants with long-term benefits and reduced side which are further expected to increase the demand for narcolepsy, thereby fuelling the market growth through 2028. Furthermore, increasing number of major players in the market focus on developing new drugs and therapies for benefit of users is further expected to increase the demand for narcolepsy, thereby supporting the market growth. According to CDC, in 2020, 34.8 % people were affected with narcolepsy or sleep disorder among U.S population.

Growing Prevalence of Narcolepsy

The growing severity of the disease and the growing number of people affected by narcolepsy due to stressful lifestyle, an inherited genetic fault, hormonal changes that take place during puberty or menopause, and a sudden change in sleep patterns are the main factors driving the growth of the market during the forecast period. Moreover, narcolepsy medications can also be used to treat sleep apnea, insomnia, and restless legs syndrome which will further drive the growth of the market.. The major drivers of the narcolepsy market growth throughout the forecast period are rising narcolepsy prevalence and a growing obese population. In addition, because it has fewer adverse effects than other stimulants, the use of modafinil to treat patients is adding to its market expansion. So, proper treatment can aid in the prevention of such ailments, which is expected to drive the global narcolepsy market. It's estimated that 1 to 4% of children suffer from sleep apnea, many of them being between 2 and 8 years old.

Download Free Sample Report

Growing Initiatives by Government Organizations

Growing awareness about narcolepsy treatment among the population is expected to create significant growth during the forecast period. Moreover, the use of modafinil to treat patients because it has fewer side effects, and it can help to prevent such disorders thereby driving the narcolepsy market during the forecast period. Government organizations from different countries such as India and South Africa have taken initiatives for campaigns to educate people and health workers about the narcolepsy drug’s advantages and narcolepsy treatment in developing as well as rural areas which is expected to boost the market growth during the forecast period. According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. The rise in donations for the development of narcolepsy treatments in the United States is further anticipated to drive the growth of the market over the years. Moreover, the rapid adoption of a new therapy for the treatment of narcolepsy drugs is anticipated to drive market growth over the forecast period. Furthermore, Project Sleep, a non-profit organization based in the United States, launched a program called "Rising Voices of Narcolepsy" to educate people about narcolepsy to share their stories through writing and verbally addressing local communities to raise awareness and reduce social stigma among others suffering from the disease.

Market Segmentation

The global narcolepsy market can be segmented on the basis of type, diagnosis, treatment, end user, and by region. Based on the type, the market can be segmented into Type 1, Type 2, and Others. Based on diagnosis, the market can be further divided into polysomnograms, multiple sleep latency test, and others. On the basis of the treatment, the market can be further split into stimulants, antidepressants, sodium oxybate, and others. Based on end users, the market can be split into hospitals, clinics, retail pharmacies, and others. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global narcolepsy market on account of the increasing incidence of sleep disorders in the country.

Recent Development

In December 2021, Ligand Pharmaceuticals, Inc. announced the expansion of its existing collaboration and license agreement between its subsidiary, Icagen and GSK. This expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
In January 2020, Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. collaborated to develop mazindol CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).

Market Players

Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc.,Graymark Healthcare, Inc. , Mylan N.V. , Teva Pharmaceutical Industries Ltd. , Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc are some of the leading players operating in the Global Narcolepsy Market.

Attribute	Details
Base Year	2022
Historic Data	2018 – 2021
Estimated Year	2023
Forecast Period	2024 – 2028
Quantitative Units	Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
Report Coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments Covered	By Type By Diagnosis By Treatment By End User By Region
Regional scope	North America, Europe, Asia Pacific, South America, Middle East & Africa
Country scope	United States, Canada, Mexico, France, Germany, United Kingdom, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, Colombia, South Africa, Saudi Arabia, UAE
Key companies profiled	Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V. , Teva Pharmaceutical Industries Ltd. , Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global narcolepsy market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Narcolepsy Market, By Type:

o Type 1

o Type 2

o Others

Narcolepsy Market, By Diagnosis:

o Polysomnogram

o Multiple Sleep Latency Test

o Others

Narcolepsy Market, By Treatment:

o Stimulants

o Antidepressants

o Sodium Oxybate

o Others

Narcolepsy Market, By Route of End User:

o Hospitals

o Clinics

o Retail Pharmacies

o Others

Narcolepsy Market, By Region:

o North America

United States
Canada
Mexico

o Europe

France
Germany
United Kingdom
Italy
Spain

o Asia Pacific

China
India
Japan
South Korea
Australia

o South America

Brazil
Argentina
Colombia

o Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Narcolepsy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials

5.2. Completed Clinical Trials

5.3. Terminated Clinical Trials

5.4. Breakdown of Pipeline, By Development Phase

5.5. Breakdown of Pipeline, By Status

5.6. Breakdown of Pipeline, By Study Type

5.7. Breakdown of Pipeline, By Region

5.8. Clinical Trials Heat Map

6. Global Narcolepsy Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type (Type 1, Type 2, Others)

6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)

6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)

6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)

6.2.5. By Company (2022)

6.3. Product Map

5.3.1 By Type

5.3.2 By Diagnosis

5.3.3 By Treatment

5.3.4 By End User

7. North America Narcolepsy Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type (Type 1, Type 2, Others)

7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)

7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)

7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)

7.2.5. By Country

7.3. North America: Country Analysis

7.3.1. United States Narcolepsy Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By Diagnosis

7.3.1.2.3. By Treatment

7.3.1.2.4. By End User

7.3.2. Canada Narcolepsy Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By Diagnosis

7.3.2.2.3. By Treatment

7.3.2.2.4. By End User

7.3.3. Mexico Narcolepsy Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By Diagnosis

7.3.3.2.3. By Treatment

7.3.3.2.4. By End User

8. Europe Narcolepsy Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Treatment Type (Chest Pain, Headache, Fever, Pneumonia, Hypertension, Fatigue, Sleep Problems)

8.2.2. By Type (Type 1, Type 2, Others)

8.2.3. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)

8.2.4. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)

8.2.5. By End User (Hospitals, Clinics, Retail Pharmacies, Others)

8.2.6. By Country

8.3. Europe: Country Analysis

8.3.1. France Narcolepsy Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type

8.3.1.2.2. By Diagnosis

8.3.1.2.3. By Treatment

8.3.1.2.4. By End User

8.3.2. Germany Narcolepsy Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type

8.3.2.2.2. By Diagnosis

8.3.2.2.3. By Treatment

8.3.2.2.4. By End User

8.3.3. United Kingdom Narcolepsy Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type

8.3.3.2.2. By Diagnosis

8.3.3.2.3. By Treatment

8.3.3.2.4. By End User

8.3.4. Italy Narcolepsy Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type

8.3.4.2.2. By Diagnosis

8.3.4.2.3. By Treatment

8.3.4.2.4. By End User

8.3.5. Spain Narcolepsy Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type

8.3.5.2.2. By Diagnosis

8.3.5.2.3. By Treatment

8.3.5.2.4. By End User

9. Asia-Pacific Narcolepsy Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type (Type 1, Type 2, Others)

9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)

9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)

9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)

9.2.5. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China Narcolepsy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

9.3.1.2.2. By Diagnosis

9.3.1.2.3. By Treatment

9.3.1.2.4. By End User

9.3.2. India Narcolepsy Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By Diagnosis

9.3.2.2.3. By Treatment

9.3.2.2.4. By End User

9.3.3. Japan Narcolepsy Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type

9.3.3.2.2. By Diagnosis

9.3.3.2.3. By Treatment

9.3.3.2.4. By End User

9.3.4. South Korea Narcolepsy Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Type

9.3.4.2.2. By Diagnosis

9.3.4.2.3. By Treatment

9.3.4.2.4. By End User

9.3.5. Australia Narcolepsy Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Type

9.3.5.2.2. By Diagnosis

9.3.5.2.3. By Treatment

9.3.5.2.4. By End User

10. South America Narcolepsy Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type (Type 1, Type 2, Others)

10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)

10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)

10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Narcolepsy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type

10.3.1.2.2. By Diagnosis

10.3.1.2.3. By Treatment

10.3.1.2.4. By End User

10.3.2. Argentina Narcolepsy Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type

10.3.2.2.2. By Diagnosis

10.3.2.2.3. By Treatment

10.3.2.2.4. By End User

10.3.3. Colombia Narcolepsy Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type

10.3.3.2.2. By Diagnosis

10.3.3.2.3. By Treatment

10.3.3.2.4. By End User

11. Middle East and Africa Narcolepsy Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Type (Type 1, Type 2, Others)

11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)

11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)

11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)

11.2.5. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Narcolepsy Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Type

11.3.1.2.2. By Diagnosis

11.3.1.2.3. By Treatment

11.3.1.2.4. By End User

11.3.2. Saudi Arabia Narcolepsy Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Type

11.3.2.2.2. By Diagnosis

11.3.2.2.3. By Treatment

11.3.2.2.4. By End User

11.3.3. UAE Narcolepsy Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Type

11.3.3.2.2. By Diagnosis

11.3.3.2.3. By Treatment

11.3.3.2.4. By End User

12. Market Dynamics

12.1. Drivers

12.1.1 Increase in Prevalence of Narcolepsy

12.1.2 Growing Initiatives by Government Organizations

12.2. Challenges

12.2.1 Adverse effect related to narcolepsy drugs.

12.2.2 Misdiagnosis related to narcolepsy treatment

13. Market Trends & Developments

13.1. Recent Development

13.2. Mergers & Acquisitions

13.3. Product Launches

14. Global Narcolepsy Market: SWOT Analysis

15. Porter’s Five Forces Analysis

15.1. Competition in the Industry

15.2. Potential of New Entrants

15.3. Power of Suppliers

15.4. Power of Customers

15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Business Overview

16.2. Product Offerings

16.3. Recent Developments

16.4. Financials (As Reported)

16.5. Key Personnel

16.6. SWOT Analysis

18.6.1 Jazz Pharmaceuticals Plc.

18.6.2 BIOPROJET.

18.6.3 Arena Pharmaceuticals, Inc.

18.6.4 Graymark Healthcare, Inc.

18.6.5 Mylan N.V.

18.6.6 Teva Pharmaceutical Industries Ltd.

18.6.7 Novartis AG.

18.6.8 Shire.

18.6.9 Shionogi Inc.

18.6.10 Ligand Pharmaceuticals, Inc.

17. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Narcolepsy Market?

The rising incidence of sleep disorders such as sleep apnea and growing awareness about narcolepsy drugs are some of the major factors driving the growth of the global Narcolepsy market.

Which are the top players operating in the Global Narcolepsy Market?

Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc, Graymark Healthcare, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc are some of the leading players operating in the Global Narcolepsy Market.